EVIO: AI 评分 47/100 — AI 分析 (4月 2026)

EVIO, Inc. provides analytical testing and advisory services to the cannabis industry in the United States. The company's services include consulting, product formulation, and testing for cannabinoid potency, pesticides, and other contaminants.

Key Facts: AI Score: 47/100 Sector: Healthcare

公司概况

概要：

EVIO, Inc. provides analytical testing and advisory services to the U.S. cannabis industry, offering consulting, product formulation, and comprehensive testing services. With a focus on cannabinoid potency, pesticide screening, and regulatory compliance, EVIO supports cannabis businesses in navigating the complex landscape of the evolving market.

EVIO是做什么的？

EVIO, Inc. was established to provide analytical testing and advisory services to businesses operating within the burgeoning cannabis industry in the United States. Recognizing the need for standardized testing and regulatory compliance in this rapidly evolving market, EVIO has positioned itself as a key service provider for cannabis cultivators, processors, and retailers. The company offers a comprehensive suite of services, including consulting, product formulation, and licensing and compliance assistance. Its analytical testing services encompass cannabinoid potency testing, terpene analysis, pesticide testing, residual solvent screening, visual inspections, and biological contaminant testing. These services are designed to ensure product safety, quality, and compliance with state and local regulations. Headquartered in Henderson, Nevada, EVIO, Inc. aims to support the growth and legitimacy of the cannabis industry by providing reliable and accurate testing and advisory solutions.

EVIO的投资论点是什么？

EVIO, Inc. presents a focused play on the cannabis testing and advisory services market. With a P/E ratio of 3.34 and a gross margin of 33.0%, the company demonstrates potential profitability. Growth catalysts include the expansion of cannabis legalization across states, driving demand for testing and compliance services. Key risks include intense competition and the evolving regulatory landscape. Investors should monitor revenue growth, profitability improvements, and the company's ability to adapt to changing regulations in the cannabis industry. The company's beta of 81.01 indicates high volatility.

EVIO在哪个行业运营？

EVIO, Inc. operates within the rapidly expanding cannabis industry, which is experiencing significant growth due to increasing legalization and acceptance across the United States. The market for cannabis testing and advisory services is becoming increasingly important as regulations tighten and consumers demand safer, more reliable products. Competition is intensifying, with numerous testing labs and consulting firms vying for market share. EVIO's success depends on its ability to maintain high standards of accuracy, compliance, and customer service in this dynamic environment.

Drug Manufacturers - Specialty & Generic

Healthcare

EVIO有哪些增长机遇？

Expansion into New Geographies: As more states legalize cannabis, EVIO has the opportunity to expand its testing and advisory services into these new markets. This geographic expansion can significantly increase its revenue base. The timeline for this growth is dependent on the pace of legalization in different states, but it represents a substantial long-term growth opportunity. By establishing testing facilities and building relationships with local cannabis businesses, EVIO can capitalize on the growing demand for its services.
Development of New Testing Services: EVIO can expand its service offerings to include more specialized testing services, such as heavy metal analysis or genetic testing of cannabis strains. These new services can attract a wider range of customers and increase revenue per client. The timeline for developing these services depends on the availability of technology and expertise, but it represents a valuable opportunity to differentiate EVIO from its competitors. This diversification can enhance EVIO's competitive advantage and market position.
Strategic Partnerships: Forming strategic partnerships with cannabis cultivators, processors, and retailers can provide EVIO with a steady stream of clients and revenue. These partnerships can also help EVIO expand its geographic reach and service offerings. The timeline for establishing these partnerships depends on the company's ability to build relationships and negotiate favorable terms. However, these partnerships can provide a significant boost to EVIO's growth and profitability.
Increased Regulatory Scrutiny: As the cannabis industry matures, regulatory scrutiny is likely to increase, driving demand for EVIO's compliance and testing services. This trend presents a significant growth opportunity for the company. The timeline for this growth is dependent on the actions of regulatory bodies, but it is likely to be a long-term trend. By staying ahead of the curve and offering comprehensive compliance solutions, EVIO can position itself as a trusted partner for cannabis businesses.
Product Formulation and Advisory Services: EVIO can leverage its expertise in cannabis testing to offer product formulation and advisory services to cannabis businesses. This can help these businesses develop new and innovative products that meet regulatory requirements and consumer demand. The timeline for this growth depends on the company's ability to attract and retain talented scientists and consultants, but it represents a valuable opportunity to expand its service offerings and increase revenue.

EVIO, Inc. operates in the cannabis analytical testing and advisory services market within the United States.
The company's profit margin is 3.0%, indicating a potential for improvement in operational efficiency.
EVIO's gross margin stands at 33.0%, reflecting its ability to manage the cost of services effectively.
The company's P/E ratio is 3.34, suggesting it may be undervalued compared to its earnings.
EVIO's beta is 81.01, indicating high volatility compared to the market.

EVIO提供哪些产品和服务？

Provides analytical testing services to the cannabis industry.
Offers consulting services related to cannabis product formulation.
Assists cannabis businesses with licensing and compliance.
Conducts cannabinoid potency testing.
Performs terpene analysis.
Screens for pesticides and residual solvents.
Conducts visual inspections of cannabis products.
Tests for biological contaminants.

EVIO如何赚钱？

Generates revenue through analytical testing services for cannabis products.
Earns fees from consulting services related to product formulation and regulatory compliance.
Partnerships with cannabis cultivators, processors, and retailers.
Offers specialized testing services, such as heavy metal analysis and genetic testing.

Cannabis cultivators
Cannabis processors
Cannabis retailers
Cannabis product manufacturers

Specialized expertise in cannabis testing and compliance.
Established relationships with cannabis businesses.
Comprehensive suite of testing and advisory services.
Reputation for accuracy and reliability.

什么因素可能推动EVIO股价上涨？

Upcoming: Expansion into new states legalizing cannabis, increasing demand for testing services.
Ongoing: Increasing regulatory scrutiny in the cannabis industry, driving demand for compliance services.
Ongoing: Strategic partnerships with cannabis cultivators, processors, and retailers.

EVIO的主要风险是什么？

Potential: Intense competition from other testing labs and consulting firms.
Potential: Evolving regulatory landscape and potential changes in cannabis laws.
Potential: Economic downturn affecting the cannabis industry.
Ongoing: Limited financial disclosure due to OTC listing.
Ongoing: Low trading volume and liquidity on the OTC market.

EVIO的核心优势是什么？

Comprehensive suite of testing and advisory services.
Expertise in cannabis testing and compliance.
Established relationships with cannabis businesses.
Reputation for accuracy and reliability.

EVIO的劣势是什么？

Small size and limited resources.
Dependence on the cannabis industry.
Limited geographic reach.
High beta indicating high volatility.

EVIO有哪些机遇？

Expansion into new geographic markets.
Development of new testing services.
Strategic partnerships with cannabis businesses.
Increased regulatory scrutiny driving demand for compliance services.

EVIO面临哪些威胁？

Intense competition from other testing labs and consulting firms.
Evolving regulatory landscape.
Potential for changes in cannabis laws.
Economic downturn affecting the cannabis industry.

EVIO的竞争对手是谁？

AnteoTech Ltd — Focuses on electrochemical detection. — (ANTCF)
Biotech Acquisition Company — Special purpose acquisition company. — (BSPK)
Forward Global — Unknown differentiation. — (FWDG)
Hemp, Inc. — Focuses on hemp-based products. — (HEMP)
Juicy Wellness Corp — Focuses on wellness and cannabis products. — (JWCAF)

Key Metrics

MoonshotScore: 47/100

Company Profile

CEO: Lori Jean Glauser
Headquarters: Henderson, US
Employees: 18
Founded: 2004

AI Insight

AI analysis pending for EVIO

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does EVIO, Inc. do?

EVIO, Inc. provides analytical testing and advisory services to businesses operating in the cannabis industry. The company offers a range of services, including cannabinoid potency testing, terpene analysis, pesticide screening, and residual solvent testing. Additionally, EVIO provides consulting services related to product formulation, licensing, and regulatory compliance. By ensuring product safety and regulatory adherence, EVIO supports the growth and legitimacy of the cannabis market.

What do analysts say about EVIO stock?

As of 2026-03-17, formal analyst ratings for EVIO are limited, likely due to its OTC listing and smaller market capitalization. Key valuation metrics include a P/E ratio of 3.34 and a gross margin of 33.0%. Growth considerations revolve around the expansion of cannabis legalization and the increasing demand for testing and compliance services. Investors should conduct their own due diligence and consider the risks associated with investing in OTC stocks.

What are the main risks for EVIO?

The main risks for EVIO include intense competition in the cannabis testing market, the evolving regulatory landscape, and potential changes in cannabis laws. The company's OTC listing also presents risks related to limited financial disclosure, low trading volume, and higher price volatility. Additionally, an economic downturn could negatively impact the cannabis industry and reduce demand for EVIO's services. Investors should carefully consider these risks before investing in EVIO.